BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29500130)

  • 1. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
    Yang J; Cheng G; Xu Q; Luan S; Wang S; Liu D; Zhao L
    Bioorg Med Chem; 2018 May; 26(8):1418-1425. PubMed ID: 29500130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
    Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.
    Li Y; Quan J; Song H; Li D; Ma E; Wang Y; Ma C
    Bioorg Chem; 2021 Sep; 114():105081. PubMed ID: 34153811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity.
    Chen X; Chen X; Steimbach RR; Wu T; Li H; Dan W; Shi P; Cao C; Li D; Miller AK; Qiu Z; Gao J; Zhu Y
    Eur J Med Chem; 2020 Feb; 187():111950. PubMed ID: 31865013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms.
    Mehndiratta S; Chen MC; Chao YH; Lee CH; Liou JP; Lai MJ; Lee HY
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):74-84. PubMed ID: 33161799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
    Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
    Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
    Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
    Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
    Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of selective histone deacetylase 6 (HDAC6) inhibitors bearing benzoindazole or pyrazoloindazole scaffold as surface recognition motif.
    Xu Q; Mou Y; Wang S; Gao X; Zhang Y; Wang Z; Xu X; Han Y; Jia W; Zhang M; Zhao L; Liu D
    Bioorg Chem; 2021 Jun; 111():104910. PubMed ID: 33894432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors.
    Morgen M; Steimbach RR; Géraldy M; Hellweg L; Sehr P; Ridinger J; Witt O; Oehme I; Herbst-Gervasoni CJ; Osko JD; Porter NJ; Christianson DW; Gunkel N; Miller AK
    ChemMedChem; 2020 Jul; 15(13):1163-1174. PubMed ID: 32348628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel hydroxamic acids bearing artemisinin skeleton.
    Ha VT; Kien VT; Binh le H; Tien VD; My NT; Nam NH; Baltas M; Hahn H; Han BW; Thao do T; Vu TK
    Bioorg Chem; 2016 Jun; 66():63-71. PubMed ID: 27018835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
    Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
    Eur J Med Chem; 2020 Mar; 190():112086. PubMed ID: 32058238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis and Biological Evaluation of a Phenyl Butyric Acid Derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 Inhibitor with Anti-proliferative Activity on Cervix Cancer and Leukemia Cells.
    Rodríguez-Fonseca RA; Sixto-López Y; Fragoso-Vázquez MJ; Flores-Mejía R; Cabrera-Pérez LC; Vázquez-Moctezuma I; Rosales-Hernández MC; Bello M; Martínez-Archundia M; Trujillo-Ferrara JG; Becerra-Martínez E; Correa-Basurto J
    Anticancer Agents Med Chem; 2017; 17(10):1441-1454. PubMed ID: 28044941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
    Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.